✦ LIBER ✦
7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN
✍ Scribed by Bracarda, S.; Bellmunt, J.; Negrier, S.N.; Melichar, B.; Ravaud, A.; Jethwa, S.; Sneller, V.; Escudier, B.
- Book ID
- 122468822
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 51 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.